Journal of the National Comprehensive Cancer Network : JNCCN最新文献

{"title":"Impact of the French ENDOCAN-COMETE Network on Overall Survival in Rare Adrenocortical Carcinomas.","authors":"Rossella Libé, Matthieu Faron, Anne-Sophie Foucan, Frederic Castinetti, Magalie Haissaguerre, Anne-Sophie Woronoff, Delphine Drui, Karima Hammas, Solange Grunenwald, Brigitte Trétarre, Patricia Delafosse, Sandrine Laboureau, Florence Molinie, Anne Cowppli-Bony, Christine Do Cao, Simona Bara, Bénédicte Lapôtre-Ledoux, Pascale Grosclaude, Sandrine D Plouvier, Gautier Defossez, Tania D'Almeida, Helene Lasolle, Bernard Goichot, Livia Lamartina, Justine Cristante, Ségolène Hescot, Marie Poiseuil, Julien Hadoux, Sophie Moog, Jérôme Bertherat, Antoine Tabarin, Gaelle Coureau, Eric Baudin","doi":"10.6004/jnccn.2025.7137","DOIUrl":"10.6004/jnccn.2025.7137","url":null,"abstract":"<p><strong>Background: </strong>Adrenocortical carcinoma (ACC) is a rare cancer. The French ENDOCAN-COMETE network was established in 2009 to coordinate care locally and nationally, and to promote research and education on malignant adrenal tumors. Evidence demonstrating the benefits of this organization is currently lacking.</p><p><strong>Patients and methods: </strong>Patients diagnosed with ACC between 2010 and 2017 were identified from the French Network of Cancer Registries (FRANCIM). Patients were categorized based on referral to the ENDOCAN-COMETE network as either referred at diagnosis (R-ACC) or not referred, or referred late (nR-ACC). Median overall survival (OS) and OS rates at 1, 5, and 10 years were compared between the R-ACC and nR-ACC groups after adjustment for prognostic parameters.</p><p><strong>Results: </strong>A total of 134 patients with ACC were identified from the FRANCIM registries, corresponding to an incidence of 1.4 cases per million person-years. Ten patients were excluded because of insufficient information regarding their health care pathway. The final analysis included 124 patients (mean age, 53.6 years; female-to-male ratio, 2:1). At diagnosis, 45.2% had European Network for the Study of Adrenal Tumours (ENSAT) stage I-II disease, 48.4% had stage III-IV disease, and 6.4% had an unknown stage; endocrine and/or tumour-related symptoms were present in 62.9% of patients. Among the analyzed patients, 87 (70%) were R-ACC, whereas 37 (30%) were nR-ACC. In patients with localized stage I-II ACC, OS rates were significantly higher in the R-ACC group than in the nR-ACC group: 1-year OS was 92% versus 85%, 5-year OS was 81% versus 55%, and 10-year OS was 75% versus 35%, respectively. This survival advantage remained significant after adjustment for prognostic factors (hazard ratio, 3.9; P=.026). In contrast, among patients with advanced ACC, OS rates were similar between the 2 groups.</p><p><strong>Conclusions: </strong>Our study demonstrates an OS benefit for patients with stage I-II ACC who were referred early to specialized centers within the ENDOCAN-COMETE network. The combined use of the French cancer registries and dedicated national networks provides the strongest evidence to date demonstrating the impact of such a network.</p>","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":"24 5","pages":""},"PeriodicalIF":16.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147944777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.","authors":"Daniel E Spratt, Sandy Srinivas, Nabil Adra, Bilawal Ahmed, Yi An, Rhonda Bitting, Brian Chapin, Heather H Cheng, Steve Y Cho, Anthony Victor D'Amico, Neil Desai, Tanya Dorff, James A Eastham, Thomas A Farrington, Xin Gao, Shilpa Gupta, Joseph E Ippolito, R Jeffrey Karnes, Amar U Kishan, Michael R Kuettel, Joshua M Lang, Daniel Lee, Tamara Lotan, Andrew McDonald, Todd M Morgan, Rodrigo Pessoa, Soroush Rais-Bahrami, Mack Roach, Tyler Robin, Stan Rosenfeld, Kristen R Scarpato, Tyler Seibert, Ahmad Shabsigh, Russell Szmulewitz, Benjamin A Teply, Jonathan Tward, Richard Valicenti, David VanderWeele, Jessica Karen Wong, Emily Kovach, Deborah Freedman-Cass","doi":"10.6004/jnccn.2026.0023","DOIUrl":"10.6004/jnccn.2026.0023","url":null,"abstract":"<p><p>The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel's discussions on select 2026 updates to the guidelines regarding nonmetastatic disease: the elimination of the very-low-risk group, updates to the Principles of Active Surveillance, and caution in the use of focal therapy in newly diagnosed patients.</p>","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":"24 5","pages":"140-149"},"PeriodicalIF":16.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147944769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social Capital and Financial Toxicity in Caregivers of Patients With Advanced Cancer: Associations With Health-Related Quality of Life and Psychological Distress.","authors":"Jin-Ah Sim, Danyu Kim, Shin Hye Yoo, Woohyeon Cho, In Young Hwang, Sun Young Lee, Kyae Hyung Kim, Min Sun Kim, Yu Jung Kim, Eun Hee Jung, Joongyub Lee, BeLong Cho","doi":"10.6004/jnccn.2025.7141","DOIUrl":"10.6004/jnccn.2025.7141","url":null,"abstract":"<p><strong>Background: </strong>Informal caregivers of patients with advanced cancer face increasing psychosocial and financial burdens; however, their health-related needs remain underrecognized. Although prior studies have examined social capital and financial toxicity separately, their combined impact on caregiver well-being is less understood. This study examined how social capital and financial toxicity are associated with caregivers' health-related quality of life (HRQoL), psychological distress, and overall health.</p><p><strong>Patients and methods: </strong>We conducted a cross-sectional survey of 200 caregivers of patients with advanced cancer at a tertiary hospital. Social capital was measured by social connectedness, group participation, and trust, whereas financial toxicity was evaluated as material burden and psychological distress related to financial concerns. Stepwise multivariate logistic regression identified factors associated with caregiver HRQoL, anxiety, depression, and self-rated health status.</p><p><strong>Results: </strong>The median age of caregivers was 50 years (IQR, 41-60); most were women (70.5%) and either a spouse or child of the patient. Approximately 50% of caregivers experienced high financial toxicity, 43% had low participation in social groups, and 42% reported low social trust. Low social connectedness (adjusted odds ratio [aOR], 2.36; 95% CI, 1.21-4.63) and high psychological distress related to financial concerns (aOR, 8.35; 95% CI, 4.27-16.31) were each significantly associated with poor HRQoL. Depression was more likely to occur among caregivers with limited social participation (aOR, 3.77; 95% CI, 1.79-7.95) and with both higher psychological distress related to financial concerns (aOR, 7.44; 95% CI, 3.79-14.60) and material burden (aOR, 2.67; 95% CI, 1.30-5.46).</p><p><strong>Conclusions: </strong>Our findings indicate that social connectedness with friends and participation in social groups were associated with better HRQoL and mental health, whereas psychological distress related to financial burden was strongly associated with poorer outcomes across all domains. Interventions designed to strengthen social support networks and alleviate financial stress may therefore be essential components of comprehensive cancer care.</p>","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":"24 5","pages":"155-162"},"PeriodicalIF":16.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147944782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JNCCN Is Moving Online.","authors":"Kimberly Callan, Daniel M Geynisman","doi":"10.6004/jnccn.2026.0024","DOIUrl":"https://doi.org/10.6004/jnccn.2026.0024","url":null,"abstract":"","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":"24 5","pages":"139"},"PeriodicalIF":16.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147949847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Hidden Cost of Cancer Caregiving in Asia.","authors":"Adrian E Go, Edward Christopher Dee","doi":"10.6004/jnccn.2026.7007","DOIUrl":"https://doi.org/10.6004/jnccn.2026.7007","url":null,"abstract":"","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":"24 5","pages":"204-205"},"PeriodicalIF":16.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147944227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Health Literacy in Breast Cancer Treatment and Outcomes.","authors":"Emma M Bradley, Palina Woodhouse, Kelvin A Moses, Megan E Salwei, Kevin W Sexton, Sunil Kripalani, Rachel L McCaffery, Kamran Idrees","doi":"10.6004/jnccn.2025.7138","DOIUrl":"10.6004/jnccn.2025.7138","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer treatment is complex, incorporating multimodality and preference-sensitive treatments dependent on oncologic characteristics, patient understanding, and shared decision-making. Health literacy (HL) is a key determinant of health in chronic disease, yet its impact in breast cancer remains undefined. This study evaluated the association of HL with receipt of breast cancer care and oncologic outcomes.</p><p><strong>Patients and methods: </strong>We performed a retrospective cohort study of patients with breast cancer diagnosed from 2005 to 2022 at a tertiary care referral center. Surgical treatment was categorized as breast conservation therapy versus mastectomy, contralateral prophylactic mastectomy, and postmastectomy reconstruction. Multivariable logistic regression and Cox proportional hazard models were used to assess associations with treatment, overall survival, and recurrence-free survival.</p><p><strong>Results: </strong>Among 3,579 patients with breast cancer, the mean [SD] Brief Health Literacy Screen (BHLS) score was 13.9 [2.1] (range, 3-15). Patients with low HL tended to be older (median age, 64 vs 58 years), non-White (21.3% vs 14.3%), and less likely to have private insurance (27.6% vs 55.6%). Adjusted for patient characteristics, higher BHLS score was protective against presenting with later-stage disease (adjusted odds ratio [aOR], 0.87; 95% CI, 0.85-0.91). Higher HL was also independently associated with an increased odds of undergoing prophylactic contralateral mastectomy (aOR, 1.07; 95% CI, 1.01-1.13) and reconstruction (aOR, 1.10; 95% CI, 1.03-1.16). There was no difference in receipt of breast conservation therapy versus mastectomy (aOR, 0.98; 95% CI, 0.94-1.02). Higher HL was associated with a decreased risk of all-cause mortality (adjusted hazard ratio [aHR], 0.91; 95% CI, 0.89-0.94) and decreased risk of recurrence (aHR, 0.92; 95% CI, 0.87-0.97).</p><p><strong>Conclusions: </strong>HL is associated with stage at presentation, surgical treatment, and survival in breast cancer. These findings highlight the importance of HL in shared decision-making for breast cancer. Assessing and addressing HL in breast cancer care has the potential to contribute to early detection, treatment decisions, and survival outcomes.</p>","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":"24 5","pages":"179-185"},"PeriodicalIF":16.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147950546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Redefining the Lymphadenectomy Standard to Avoid Understaging in Oncologic Colectomies.","authors":"Praveen D Chatani, Jordan D Fredette, James Sun, Rosmi P Thomas, Andrea S Porpiglia, Stephanie H Greco, Sanjay S Reddy, Jeffrey M Farma, Anthony M Villano","doi":"10.6004/jnccn.2025.7122","DOIUrl":"10.6004/jnccn.2025.7122","url":null,"abstract":"<p><strong>Background: </strong>Accurate identification of positive lymph nodes after colectomy is essential for optimizing oncologic outcomes, as it directly informs the use of adjuvant chemotherapy in nonmetastatic colon cancer. The current lymph node target required for accurate staging has remained unchanged for decades. This study sought to identify a data-driven lymph node threshold that better optimizes oncologic outcomes.</p><p><strong>Methods: </strong>The National Cancer Database was queried for patients with clinically node-negative colon adenocarcinoma undergoing curative-intent resection between 2010 and 2021. Variables associated with nodal positivity were identified and the likelihood of nodal positivity with increasing lymph node examination targets was assessed.</p><p><strong>Results: </strong>Clinically node-negative patients who underwent curative-intent colectomy (n=195,009) were found to be node-positive in 26.3% of cases. Characteristics associated with nodal positivity included lymphovascular or perineural invasion, poor differentiation, microsatellite stability, age <50 years, and sigmoid primary. The number of nodes examined correlated with increased odds of pathologic node-positive disease at varying rates (11.2% per node for the first 10 nodes, 1.2% per node from 11-26 nodes, with no correlation beyond 26 nodes). Examination of ≥18 nodes was independently associated with pathologic nodal positivity (odds ratio [OR], 1.11), receipt of adjuvant chemotherapy (OR, 1.10), and improved median overall survival (hazard ratio, 0.88) when compared with those with 12 to 17 nodes examined (all P<.05).</p><p><strong>Conclusions: </strong>Our study demonstrates the superiority of a predetermined higher lymph node examination target (≥18 nodes) compared with the current standard. This target more frequently identified stage III disease and was associated with higher rates of adjuvant chemotherapy use and improved overall survival.</p>","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147582883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative Systemic Treatment Options for Muscle-Invasive Bladder Cancer.","authors":"Jason R Brown, Mamta Parikh","doi":"10.6004/jnccn.2026.7034","DOIUrl":"10.6004/jnccn.2026.7034","url":null,"abstract":"<p><p>Radical cystectomy has long been the standard of care for muscle-invasive bladder cancer (MIBC), an aggressive cancer with a high risk of progression to recurrent or metastatic disease. Systemic therapy has improved survival outcomes for these patients, with administration in neoadjuvant, adjuvant, and, more recently, \"sandwich\" perioperative settings. Cisplatin-based therapies have been the mainstay of neoadjuvant treatment for patients without comorbidities who are considered eligible for this chemotherapy. Immune checkpoint inhibition has more recently shown promise not only in prospective single-arm neoadjuvant clinical trials, but also in demonstrating significant improvement in disease-free survival when administered adjuvantly in patients at high risk of recurrence based on residual disease at the time of cystectomy. Furthermore, a biomarker-adapted approach in which patients with detectable postoperative circulating tumor DNA (ctDNA) are selected appears to enhance identification of those most likely to benefit from adjuvant immune checkpoint inhibition. Alternatively, a novel paradigm adopting a combination of preoperative and postoperative therapy sandwiched around cystectomy has been adopted in contemporary clinical trials. Two of these perioperative regimens-cisplatin/gemcitabine/durvalumab and enfortumab vedotin/pembrolizumab-have yielded significant improvements in survival for patients with MIBC and appear poised to become the dominant systemic therapy paradigm for those with MIBC undergoing radical cystectomy. With these advances, opportunities remain to further improve patient outcomes and potentially synthesize these response-adaptive and perioperative approaches. Future studies will address the contribution of postoperative therapy and may ultimately identify patients for whom cystectomy can be deferred altogether.</p>","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":"24 5","pages":""},"PeriodicalIF":16.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147944776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methylphenidate-Type Psychostimulants for Cancer-Related Fatigue: Updated Meta-Analysis of Randomized Controlled Trials.","authors":"Bruno Almeida Costa, Richard Sheppard, Henrique G B Coelho, Fionnuala Crowley, Debora Oliveira, Victor Almeida Costa, Joanna Chen, Debora Afezolli, Gene A DeCastro, Olusegun Apoeso, Beth Popp, Kimberly A Curseen, Tammie E Quest","doi":"10.6004/jnccn.2025.7135","DOIUrl":"10.6004/jnccn.2025.7135","url":null,"abstract":"<p><strong>Background: </strong>Nonpharmacologic interventions are the mainstay of management for cancer-related fatigue (CRF), with few pharmacologic options available-notably methylphenidate (MPH) and dexmethylphenidate (d-MPH). Given mixed evidence from randomized controlled trials (RCTs) and newly published phase III data, we conducted an updated systematic review and meta-analysis to clarify the efficacy and safety of these psychostimulants in managing CRF.</p><p><strong>Methods: </strong>PubMed, Embase, and CENTRAL were searched through January 2025 for placebo-controlled, double-blind RCTs evaluating MPH/d-MPH in adults with advanced cancer or receiving active cancer-directed therapy. Outcomes included between-group differences in fatigue score changes measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), self-rated 0-10 scales, or any validated scales, as well as treatment-emergent adverse events (TEAEs). Exploratory subanalyses examined FACIT-F score changes at 2 ± 1, 5 ± 1, and ≥8 weeks after treatment initiation. Pooled estimates were calculated using random-effects models.</p><p><strong>Results: </strong>A total of 9 RCTs met inclusion criteria (n=823; with evaluable sample sizes varying per analysis). Compared with placebo, MPH/d-MPH monotherapy (MPH-equivalent dose range: 5-100 mg/d) produced statistically significant improvements in fatigue scores, as measured by FACIT-F (mean difference [MD], 2.43; 95% CI, 0.90 to 3.96), self-rated 0-10 scales (MD, -1.52; 95% CI, -2.90 to -0.14), and any validated scale (standardized MD, 0.38; 95% CI, 0.17 to 0.60). FACIT-F improvements followed a temporal gradient, exceeding the 3-point threshold for clinical meaningfulness by 5 ± 1 weeks (MD, 3.56; 95% CI, 1.57 to 5.55) and rising further by ≥8 weeks (MD, 3.89; 95% CI, 1.76 to 6.01). No statistically significant differences in the odds of key TEAEs were observed.</p><p><strong>Conclusions: </strong>MPH-type psychostimulants produce a modest but consistent reduction in CRF, with therapeutic benefits becoming clinically meaningful after 5 weeks and a favorable safety profile in the studied population, thereby meriting consideration for carefully selected individuals living with cancer when nonpharmacologic strategies are insufficient or still taking effect.</p>","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":"24 5","pages":"163-171"},"PeriodicalIF":16.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147950214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recommended Terms and Definitions From the 2025 NCCN Biomarkers Resource Committee.","authors":"Melissa Y Tjota, Jennelle C Hodge, Lawrence J Jennings, Kimberly Allison, Ahmet Dogan, Tamara L Lotan, Valentina Nardi, Tuya Pal, Svitlana Ostanina, Marian L Birkeland, Dara L Aisner, Fei Dong","doi":"10.6004/jnccn.2026.7021","DOIUrl":"10.6004/jnccn.2026.7021","url":null,"abstract":"<p><p>The NCCN Biomarkers Resource Committee (BRC) was established to provide molecular expertise and guidance related to key aspects of biomarker testing in NCCN publications. A key aim is to reduce inconsistencies and standardize biomarker testing terms and definitions for suggested use across all NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). The key areas found to need terminology clarification and harmonization included those describing types of genomic events and testing approaches. For these areas, current professional society guidelines regarding terminology, utilization within current guidelines, and common parlance in practice were explored. Synonyms were also identified. Each area was discussed to nominate preferred (and, when applicable, nonpreferred) terminology with a rationale. The aims of this document are to define commonly used terms for clinical care providers and provide recommendations for the standardized use of this biomarker terminology within NCCN Guidelines and publications.</p>","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147795449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}